Cargando…

Development of a Humanized VHH Based Recombinant Antibody Targeting Claudin 18.2 Positive Cancers

Claudin 18.2 (CLDN18.2), a tight junction (TJ) family protein controlling molecule exchange between cells, is frequently over-expressed in gastric cancer, pancreatic adenocarcinomas and in a fraction of non–small cell lung cancer cases. The tumor properties indicate that CLDN18.2 could be an attract...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhong, Weixiang, Lu, Yimin, Ma, Zhe, He, Yinjun, Ding, Yongfeng, Yao, Gaofeng, Zhou, Zhenxing, Dong, Jiali, Fang, Yongliang, Jiang, Weiqin, Wang, Weilin, Huang, Yanshan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9273722/ https://www.ncbi.nlm.nih.gov/pubmed/35837391 http://dx.doi.org/10.3389/fimmu.2022.885424

Ejemplares similares

Development and comparison of (68)Ga/(18)F/(64)Cu-labeled nanobody tracers probing Claudin18.2
por: Wei, Weijun, et al.
Publicado: (2022)

Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody
por: Bähr-Mahmud, Hayat, et al.
Publicado: (2023)

VHH-Based Bispecific Antibodies Targeting Cytokine Production
por: Nosenko, Maxim A., et al.
Publicado: (2017)

Claudin18.who? Examining biomarker overlap and outcomes in claudin18.2-positive gastroesophageal adenocarcinomas
por: Klempner, S.J., et al.
Publicado: (2023)

Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer
por: Singh, Prabhsimranjot, et al.
Publicado: (2017)

IL-15 armoring enhances the antitumor efficacy of claudin 18.2-targeting CAR-T cells in syngeneic mouse tumor models
por: Shi, Hongtai, et al.
Publicado: (2023)

Prognostic impact of Claudin 18.2 in gastric and esophageal adenocarcinomas
por: Arnold, A., et al.
Publicado: (2020)

Prognostic value of claudin 18.2 expression in gastric adenocarcinoma
por: Kayikcioglu, Erkan, et al.
Publicado: (2023)

Exhausted CD8+T Cells in the Tumor Immune Microenvironment: New Pathways to Therapy
por: Jiang, Weiqin, et al.
Publicado: (2021)

The role of claudin 18.2 and HER-2 in pancreatic cancer outcomes
por: Kayikcioglu, Erkan, et al.
Publicado: (2023)

Evaluation and reflection on claudin 18.2 targeting therapy in advanced gastric cancer
por: Zhang, Jianwei, et al.
Publicado: (2020)

Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy
por: Cao, Weijie, et al.
Publicado: (2022)

Antigen-Specific T Cell Immunotherapy Targeting Claudin18.2 in Gastric Cancer
por: Xu, Bo, et al.
Publicado: (2022)

Neutralizing epitopes on Clostridioides difficile toxin A revealed by the structures of two camelid VHH antibodies
por: Chen, Baohua, et al.
Publicado: (2022)

Clinicopathologic Relevance of Claudin 18.2 Expression in Gastric Cancer: A Meta-Analysis
por: Ungureanu, Bogdan Silviu, et al.
Publicado: (2021)

Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma
por: Wang, Xi, et al.
Publicado: (2022)

Claudin 18.2 expression in esophageal adenocarcinoma and its potential impact on future treatment strategies
por: Moentenich, Valeska, et al.
Publicado: (2020)

CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer
por: Qi, Changsong, et al.
Publicado: (2023)

Clinicopathologic features and prognostic value of claudin 18.2 overexpression in patients with resectable gastric cancer
por: Kim, Hyung-Don, et al.
Publicado: (2023)

Genomic and transcriptomic analysis of MSI-H colorectal cancer patients with targetable alterations identifies clinical implications for immunotherapy
por: Hua, Hanju, et al.
Publicado: (2023)

Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results
por: Qi, Changsong, et al.
Publicado: (2022)

Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer
por: Kubota, Y., et al.
Publicado: (2023)

Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma
por: Rohde, Christoph, et al.
Publicado: (2019)

GlycoVHH: optimal sites for introducing N-glycans on the camelid VHH antibody scaffold and use for macrophage delivery
por: van Schie, Loes, et al.
Publicado: (2023)

A Tetraspecific VHH-Based Neutralizing Antibody Modifies Disease Outcome in Three Animal Models of Clostridium difficile Infection
por: Schmidt, Diane J., et al.
Publicado: (2016)

VHH Antibodies: Reagents for Mycotoxin Detection in Food Products
por: Wang, Jia, et al.
Publicado: (2018)

Molecular recognition requires dimerization of a VHH antibody
por: Smith, Christopher A., et al.
Publicado: (2023)

Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer
por: Hong, Jung Yong, et al.
Publicado: (2020)

Claudin18.2 bispecific T cell engager armed oncolytic virus enhances antitumor effects against pancreatic cancer
por: Liu, Shiyu, et al.
Publicado: (2023)

Case Report: A rare case of recurrent ascites after anti-Claudin18.2 antibody therapy for metastatic gastric cancer while responding sustainingly
por: Liu, Jinlu, et al.
Publicado: (2023)

The Availability of a Recombinant Anti-SNAP Antibody in VHH Format Amplifies the Application Flexibility of SNAP-Tagged Proteins
por: Aliprandi, Marisa, et al.
Publicado: (2010)

FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer
por: Liu, Yifan, et al.
Publicado: (2023)

ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2–Positive Gastric or Gastroesophageal Junction Adenocarcinoma
por: Klempner, Samuel J., et al.
Publicado: (2023)

Use of VHH antibodies for the development of antigen detection test for visceral leishmaniasis
por: Abeijon, Claudia, et al.
Publicado: (2018)

Brain Delivery of Single-Domain Antibodies: A Focus on VHH and VNAR
por: Pothin, Elodie, et al.
Publicado: (2020)

Expression of the potential therapeutic target claudin-18.2 is frequently decreased in gastric cancer: results from a large Caucasian cohort study
por: Dottermusch, Matthias, et al.
Publicado: (2019)

MiRNA-182-5p aggravates experimental ulcerative colitis via sponging Claudin-2
por: Tang, Siwen, et al.
Publicado: (2021)

Bacterial cytoplasm as an effective cell compartment for producing functional VHH-based affinity reagents and Camelidae IgG-like recombinant antibodies
por: Djender, Selma, et al.
Publicado: (2014)

MicroRNA-183/96/182 cluster in immunity and autoimmunity
por: Wang, Zhuang, et al.
Publicado: (2023)

CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation
por: Gao, Jing, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_578mnc6g7one2bh63p1v0dmhb8